Evidence map›Paper›PMID 27777897›Full record

ArticleJournal of clinical and translational hepatology2016

Chronic Cholestatic Liver Injury Attributable to Vedolizumab.

Jonathan G Stine, Jennifer Wang, Brian W Behm

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and translational hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Vedolizumab-Induced Liver Injury.GE Portuguese journal of gastroenterology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jonathan G StineDivision of Gastroenterology & Hepatology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.
Jennifer WangDepartment of Medicine, University of Virginia, Charlottesville, VA, USA.
Brian W BehmDivision of Gastroenterology & Hepatology, Department of Medicine, University of Virginia, Charlottesville, VA, USA.

Funding

RESEARCH TRAINING IN DIGESTIVE DISEASEST32DK007769 · NIDDK · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI COHN, STEVEN M · 1999 to 2014
$2.1M
NIDDK NIH HHS T32 DK007769
6 · The paper itself

Abstract

Drug-induced liver injury is a rare but clinically important diagnosis. Vedolizumab is an α4β7 integrin inhibitor recently approved for use in patients with moderate-to-severe inflammatory bowel disease. Cases of hepatoxicity due to vedolizumab in the pre-marketing stage were rare, and all cases resolved upon drug withdrawal. We present here the first reported case of hepatotoxicity attributable to vedolizumab, which despite drug cessation persisted with chronic cholestatic liver injury.

Indexed as

HepatotoxicityInflammatory bowel diseaseIntegrin inhibitorPrimary sclerosing cholangitis

Identifiers

PMID27777897
PMCPMC5075012

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.